FGFR3 and transitional cell carcinoma: Vofatamab (B-701) is yet another promising FGFR3 monoclonal antibody in clinical development, and was shown to be well tolerated in combination with docetaxel in patients with urothelial cell carcinoma in the FIERCE-21 study (NCT02041542).77 Not surprisingly, enhanced activity was observed in patients with FGFR3 mutations or fusions compared with wild-type patients.